×
About 2,963 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  905 results

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tum...
https://doi.org/10.1002/cam4.5044
Cancer Medicine; Attia S, Bolejack V et. al.

Aug 12th, 2022 - Regorafenib is one of several FDA-approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype-specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of reg...

Delayed appearance of refeeding syndrome in a patient with anorexia nervosa: A case rep...
https://doi.org/10.1016/j.nut.2022.111788
Nutrition (Burbank, Los Angeles County, Calif.); Iacopelli M, Cereda E et. al.

Aug 12th, 2022 - Refeeding syndrome (RFS) can be a severe and life-threatening complication of anorexia nervosa (AN) associated with electrolyte abnormalities and organ damage, and occurs with the transition from a prolonged catabolic to anabolic state, particular...

Late onset Bartter syndrome: Bartter syndrome type 2 presenting with isolated nephrocal...
https://doi.org/10.1515/jpem-2022-0154
Journal of Pediatric Endocrinology & Metabolism : JPEM; Yıldız G, Torun Bayram M et. al.

Aug 12th, 2022 - Nephrocalcinosis is associated with conditions that cause hypercalcemia and the increased urinary excretion of calcium, phosphate, and/or oxalate. A monogenic etiology is found in almost 30% of childhood-onset nephrocalcinosis which is also a comm...

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multi...
https://doi.org/10.1002/hon.3066
Hematological Oncology; Berenson JR, Kim C et. al.

Aug 11th, 2022 - Ruxolitinib with lenalidomide and dexamethasone shows anti-myeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma (MM) cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity...

Hypophosphatemia: A Practical Guide to Evaluation and Management.
https://doi.org/10.1016/j.eprac.2022.07.005
Endocrine Practice : Official Journal of the American Col... Tebben PJ

Aug 9th, 2022 - Phosphate plays a critical and diverse role in human physiology. In addition to it is importance in skeletal mineralization, it is essential for energy homeostasis, enzyme function, and cell membrane integrity. These diverse functions of provide a...

see more →

Drugs  103 results see all →

Clinicaltrials.gov  72 results

Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?
https://clinicaltrials.gov/ct2/show/NCT02420119

Aug 9th, 2022 - Intravenous iron replacement has become quite common in cases where oral iron therapy is insufficient or poorly tolerated. Various intravenous iron preparations have been used in patients on dialysis and with chronic kidney disease for many years,...

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
https://clinicaltrials.gov/ct2/show/NCT03489993

Aug 5th, 2022 - Clinical data will be collected from the Electronic Medical Record, including age, sex, parent-reported race, past medical and family histories, and current medications. The investigators will calculate body mass index and define overweight/obesit...

X-linked Hypophosphatemia Disease Monitoring Program
https://clinicaltrials.gov/ct2/show/NCT03651505

Aug 1st, 2022 - The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of burosu...

Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care
https://clinicaltrials.gov/ct2/show/NCT05474157

Jul 26th, 2022 - Patients with acute respiratory distress syndrome (ARDS) could develop muscle weakness associated with impairment of physical function defined as intensive care unit acquired weakness. Significant muscle loss occurs in the first week of the Intens...

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
https://clinicaltrials.gov/ct2/show/NCT03478839

Jul 7th, 2022 - This is a natural history study of patients with Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). GACI is an ultra-rare disorder with an estimated birth prevalence of around 1 in ...

see more →

News  105 results

X-Linked Hypophosphatemia Exacts Early, High Toll on Musculoskeletal System
https://www.medscape.com/viewarticle/962020

Nov 2nd, 2021 - NEW YORK (Reuters Health) - Adults with X-linked hypophosphatemia (XLH) have high rates of musculoskeletal problems that start as early as age 20 years and gradually accumulate over the years, a new analysis confirms. XLH is a rare inherited disor...

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer
https://www.onclive.com/view/dr-sonpavde-on-the-safety-profile-of-erdafitinib-in-bladder-cancer

Oct 6th, 2021 - Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the safety profile of erdafitinib (Balversa), which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metas...

HR-positive breast cancer: Entinostat fails phase 3 trial
https://www.mdedge.com/hematology-oncology/article/245091/breast-cancer/hr-positive-breast-cancer-entinostat-fails-phase-3

Aug 31st, 2021 - Key clinical point: Adding entinostat to e xemestane does not improve survival in aromatase inhibitor (AI)-resistant advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Major finding: Th.

Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
https://www.onclive.com/view/pembrolizumab-cabozantinib-combo-provides-benefit-in-mrcc

Jul 1st, 2021 - The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) induced a response in more than half of patients with metastatic renal cell carcinoma (mRCC) at the recommended phase 2 dose (RP2D) with a manageable safety profile, meeting ...

Camidanlumab Tesirine Elicits Encouraging ORR in Heavily Pretreated Hodgkin Lymphoma
https://www.onclive.com/view/camidanlumab-tesirine-elicits-encouraging-orr-in-heavily-pretreated-hodgkin-lymphoma

Jun 22nd, 2021 - Camidanlumab tesirine (ADCT-301) was found to elicit an objective response rate (ORR) of 66.3% in patients with relapsed/refractory Hodgkin lymphoma, according to interim data from a phase 2 study (NCT04052997) presented during the 16th Internatio...

see more →